An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
SpringWorks Therapeutics, a biopharmaceutical company, will report its first quarter 2024 financial results on May 2, 2024. The company focuses on severe rare diseases and cancer. Investors can join a live conference call and webcast to discuss the financial results and recent business updates.
SpringWorks Therapeutics, un'azienda biofarmaceutica, riporterà i risultati finanziari del primo trimestre 2024 il 2 maggio 2024. La società si concentra su malattie rare gravi e sul cancro. Gli investitori possono partecipare a una conferenza telefonica e a un webcast in diretta per discutere i risultati finanziari e gli aggiornamenti recenti dell'attività.
SpringWorks Therapeutics, una compañía biofarmacéutica, informará sus resultados financieros del primer trimestre de 2024 el 2 de mayo de 2024. La empresa se centra en enfermedades raras graves y cáncer. Los inversores pueden unirse a una llamada de conferencia y transmisión web en vivo para discutir los resultados financieros y las actualizaciones recientes del negocio.
바이오 제약 회사인 SpringWorks Therapeutics가 2024년 1분기 재무 결과를 2024년 5월 2일에 발표할 예정입니다. 이 회사는 심각한 희귀 질병과 암에 중점을 두고 있습니다. 투자자들은 재무 결과와 최근 사업 업데이트에 대해 논의하기 위해 라이브 컨퍼런스 콜과 웹캐스트에 참여할 수 있습니다.
SpringWorks Therapeutics, une entreprise biopharmaceutique, communiquera ses résultats financiers du premier trimestre 2024 le 2 mai 2024. L'entreprise se concentre sur les maladies rares sévères et le cancer. Les investisseurs peuvent rejoindre une conférence téléphonique et une webdiffusion en direct pour discuter des résultats financiers et des mises à jour récentes de l'entreprise.
SpringWorks Therapeutics, ein biopharmazeutisches Unternehmen, wird seine Finanzergebnisse für das erste Quartal 2024 am 2. Mai 2024 bekannt geben. Das Unternehmen konzentriert sich auf schwere seltene Krankheiten und Krebs. Investoren können an einem Live-Telefonkonferenzgespräch und Webcast teilnehmen, um die Finanzergebnisse und aktuelle Geschäftsneuigkeiten zu besprechen.
Positive
None.
Negative
None.
STAMFORD, Conn., April 18, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. E.T. on Thursday, May 2, 2024 to report its first quarter financial results and discuss recent business updates.
To join the live webcast and view the corresponding slides, please click here. To access the live call by phone, please pre-register for the call by clicking here. Once registration is complete, participants will be provided with a dial-in number and conference code to access the call. A replay of the webcast will be available for a limited time following the event on the Investors and Media section of the Company’s website at https://ir.springworkstx.com.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company’s first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.
springworks therapeutics is a mission-driven medicines company dedicated to developing innovative potential new treatments for unserved and underserved patient communities. originally conceived by pfizer, springworks presents a groundbreaking new model for collaboration rooted in connecting scientists, biopharmaceutical partners, patient groups, funders and philanthropists to advance and deliver transformative science to patients. through our partnerships, we remain focused on providing innovative treatments an additional avenue for development, with our launch pipeline focused on advancing potential programs for four diseases, all of which currently have no cure, including desmoid tumor, neurofibromatosis, hereditary xerocytosis and post-traumatic stress disorder. our name is a reflection of our approach to drug development: we’re springing into action to deliver treatments to people who are in great need and without alternatives.
